Navigation Links
Caris Life Sciences Symposium to Explore Advances in Next Generation Sequencing for Gynecologic Cancers
Date:3/8/2013

sights about the genomics of the disease."

The application of NGS technologies holds significant promise in the treatment of ovarian cancer, the most lethal gynecologic cancer in the U.S., resulting in approximately 14,000 deaths annually.1 Although primary ovarian carcinomas initially respond to platinum-based therapy, this response is often incomplete, resulting in relapse in almost 80% of women with advanced disease.2‐4 It's therefore critical to thoroughly assess the entire biology of a tumor using NGS technology, along with more traditional profiling technologies like IHC and FISH.

"Given the high recurrence rate and poor long‐term survival of women with advanced ovarian cancer, there is an urgent need for improved methods of biomarker target identification, chemotherapy selection and clinical trials enrollment," explained Dr. Coleman. "Ovarian neoplasms differ widely with respect to their clinical behavior and response to chemotherapy, suggesting that each patient's disease may harbor unique, clinically actionable molecular targets. When paired with traditional gold-standard pathology, NGS information has the promise to lead to superior therapeutic associations, more rapid and efficient identification of candidates for new clinical trials, and ultimately, better patient management."

In addition to Dr. Coleman, the symposium faculty includes the below experts, whose presentations will address the following topics:

  • NGS Targets in Ovarian Carcinoma: Ryan Bender , Ph.D, FACMG, Director, Molecular Genetics, Caris Life Sciences
  • Integrating NGS Data Into Patient Care – Today: Deborah Zajchowski , Ph.D, Clearity Foundation
  • The Future of Tumor Profiling in Gynecologic Cancers: Maurie Markman , M.D., SVP & National Director of Medical Oncology
    '/>"/>

SOURCE Caris Life Sciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Caris Life Sciences Enhances Molecular Profiling Service with Addition of ROS1 and MGMT-Methylation Biomarkers
2. Caris Life Sciences mejora la evaluación por perfil molecular con los biomarcadores ROS1 y MGMT-metilación
3. Caris Sponsors CancerCare Connect Education Workshop on Molecular Profiling in the Treatment of Breast Cancer
4. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
5. Caris Life Sciences nimmt Next-Generation Sequencing zur Verbesserung des evidenzbasierten Tumorprofilierungsservices für Krebspatienten auf
6. Garage Start-ups Now Possible in Life Sciences Industry
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. DiaTech Life Sciences Announces Medical Advisory Board
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... 4, 2015 In an article published and ... for Health Security review the clinical aspects of diseases ... as bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related ... website of the New England Journal of Medicine ... Toner , and Tom Inglesby—review the clinical management of ...
(Date:3/4/2015)... 04, 2015 USDM Life Sciences ... life sciences industry, hired David Blewitt as ... Cloud Compliance Services and Solutions at USDM Life Sciences ... applications while maintaining compliance with government regulations worldwide. ... an accomplished life sciences regulatory and IS compliance professional ...
(Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix Corp. ... has completed a collaborative research program with ...  Using Fast Collective Evolution Technology (FACET), Emerald ... all measurements obtained from each of 798 ... 2 clinical trials ASSERT, SUSTAIN and ASSURE. ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... the first ... ... dollars, QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Atrium Innovations Inc.,(TSX: ATB), ... and nutrition industries, announced today,his financial results for the first quarter of ...
... MINRAD,International, Inc. (Amex: BUF ) today announced that ... aggregate of $40.0 million of senior,secured convertible notes with ... The notes pay an 8% coupon, have a 3 ... The aggregate net,proceeds of the notes, after deducting the ...
... Conn., May 5 VION PHARMACEUTICALS,INC. (Nasdaq: VION ... March 31, 2008., The Company reported a net ... three-month period ended March 31, 2008, compared with a ... the same period in 2007.,Weighted-average common shares outstanding for ...
Cached Biology Technology:Atrium shows a strong financial performance for its first quarter 2Atrium shows a strong financial performance for its first quarter 3Atrium shows a strong financial performance for its first quarter 4Atrium shows a strong financial performance for its first quarter 5MINRAD International, Inc. Announces $40.0 Million Private Placement 2MINRAD International, Inc. Announces $40.0 Million Private Placement 3Vion Reports 2008 First Quarter Results 2Vion Reports 2008 First Quarter Results 3Vion Reports 2008 First Quarter Results 4
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... the developing world, has announced the winners of the TWAS ... and be invited to lecture about his or her research ... place in Mexico City from 10 to 13 November 2008. ... Environmental Sciences, University of Agriculture, Faisalabad, Pakistan, has won the ...
... LAFAYETTE, Ind. - Pre-malignant mammary lesions in dogs and ... that could lead to better understanding of breast cancer ... Purdue University scientist from the School of Veterinary Medicine. ... found similarities between benign lesions that are considered to ...
... 2007 The American Physiological Society (APS; ... its prestigious Bodil M. Schmidt-Nielsen Distinguished Mentor and Scientist ... of Mississippi Medical Center. The honor, now in ... APS who have made outstanding contributions to physiological research ...
Cached Biology News:TWAS announces 2007 prize winners 2TWAS announces 2007 prize winners 3TWAS announces 2007 prize winners 4Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 2Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 3Purdue research finds similarities in dog, human breast cancer pre-malignant lesions 4Granger wins Schmidt-Nielsen Mentor/Scientist Award 2
...
Luminometers...
... Designed for serial preparation ... fractions including cytosol/particulate/cytoskeleton/nuclear fractions ... these fractions can directly ... assays such as 2-D ...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
Biology Products: